_safety-and-efficacy-of-the-oral-atr-inhibitor-elimusertib-in-advanced-solid-tumours-with-dna-damage-response-defects.jpg "Safety and efficacy of the oral ATR inhibitor elimusertib in advanced solid tumours with DNA damage response defects from ataxia telangiectasia Video Screenshot Preview")
GalleryPlay Video:
(Note: The default playback of the video is HD VERSION. If your browser is buffering the video slowly, please play the REGULAR MP4 VERSION or Open The Video below for better experience. Thank you!)
⏲ Duration: 2 min 49 sec
✓ Published: 11-Apr-2022
✓ Published: 11-Apr-2022
Description:
Dr Timothy Yap speaks to ecancer as part of the AACR 2022 meeting about a study evaluating the safety and efficacy of the oral ataxia telangiectasia and Rad3-related (ATR) inhibitor elimusertib in advanced solid tumours with DNA damage response defects.nnHe reports that clinical benefit with disease control for at least 16 weeks was achieved in at least 35% of patients treated with elimusertib and that durable responses were seen over a variety of cancer types. nnDr Yap also explains that the ad
Dr Timothy Yap speaks to ecancer as part of the AACR 2022 meeting about a study evaluating the safety and efficacy of the oral ataxia telangiectasia and Rad3-related (ATR) inhibitor elimusertib in advanced solid tumours with DNA damage response defects.nnHe reports that clinical benefit with disease control for at least 16 weeks was achieved in at least 35% of patients treated with elimusertib and that durable responses were seen over a variety of cancer types. nnDr Yap also explains that the ad
Share with your friends:
Whatsapp | Viber | Telegram | Line | SMS
Email | Twitter | Reddit | Tumblr | Pinterest
Related Videos
_the-veldink-family-talks-about-ataxia-telangiectasia.webp "Andy Phelps")
_matinntak-og-ernringsstatus-ved-ataxia-telangiectasia.webp "Gro Trae, klinisk ernæringsfysiolog, FrambunFra kurs på Frambu 24. februar 2016")
_national-ataxia-telangiectasia-a-t-clinic-ten-news-segment.webp "Wesley Research Institute")
_ataxia-telangiectasia-rapid-review-primary-immunodeficiencies-chapter-of-the-achiever39s-course.webp "The Achiever's Edge By Dr Sandeep Sharma")
⏲ 4 minutes 51 seconds 👁 1.2K
_lee.webp "Ataxia telangiectasia is a rare neurodegenerative disease, one that has left Lee severely disabled. But not one that makes him sad or unhappy with life, as thankfully he has a family who care and are there for him and all his needs… Meet Lee and A.T.")
_silicon-valley-prayer-breakfast-2010-03-31.webp "The 2010 event featured Joe Ehrmann, former NFL player, coach, and community leader, and Tim Borland, president of Race for Good. The theme of the event was")
_imagin-at-film.webp "Dr Jayesh Bhatt and Dr Andrew Prayle talk about their IMAGIN-AT research project at Nottingham University Hospital")
_causes-and-drug-development-in-ataxia-telangiectasia.webp "Dr Richard Gatti meets with ecancertv to discuss Ataxia telangiectasia (AT), a rare, and some times lethal, disorder in children where one out of three develops malignancy by the age of ten.nnDr Gatti notes that children with AT have a very strong cancer predisposition because they are missing the ATM protein which causes cell death by apoptosis; however, it is still unclear has to how this results in the development of cancer cells. Dr Gatti is currently working on the development of a group of")
_the-veldink-family-talks-about-ataxia-telangiectasia.jpg)
_matinntak-og-ernringsstatus-ved-ataxia-telangiectasia.jpg)
_national-ataxia-telangiectasia-a-t-clinic-ten-news-segment.jpg)
_ataxia-telangiectasia-rapid-review-primary-immunodeficiencies-chapter-of-the-achiever39s-course.jpg)
_lee.jpg)
_silicon-valley-prayer-breakfast-2010-03-31.jpg)
_imagin-at-film.jpg)
_causes-and-drug-development-in-ataxia-telangiectasia.jpg)
![[+]](/images/menu.gif){kind=small}